2012 ANNUAL REPORT

The Bottini Brothers
Success in Arthritis Research
page 4

The Latest Arthritis Research
page 7

"#1 Charity to Watch!"
★★★★★ - from Charity Navigator - page 2
End the pain of arthritis. That’s what we at the Arthritis National Research Foundation seek to do by funding scientific research. We continue to work to earn your trust in ANRF’s ability to fund the best research and scientists to reach this goal.

ANRF keeps its overhead costs to a minimum and provides complete transparency of its governance and operations. This effort was recognized recently by the independent charity evaluator, Charity Navigator, by naming the Arthritis National Research Foundation the “#1 Charity to Watch” in a list of 10 exemplary charities with budgets under $2 million.

We could not be more delighted with this rating from Charity Navigator. But there is more we can do. Not only do we pledge to continuously work to fund the scientists with the best possible opportunities to find new treatments and move the research forward, but we are going one step further. ANRF has asked a blue-ribbon panel of three world-renowned scientists who are recognized experts in the fields of rheumatology and immunology to provide an independent assessment of our organization. This team will evaluate and report on ANRF’s impact in the research field. Their professional expertise in the research and clinical aspects of arthritis and autoimmune diseases provides the critical perspective needed to perform this evaluation.

The results of this assessment will be posted on our website when completed later this year.

ANRF is the charity that funds research to cure arthritis. I entreat you to read about this year’s grant recipients and their cutting-edge research projects. Please go to our website and visit the section entitled, “Research Success” when you click from the home page on “Transparency and Accountability.” We take you from science to results in language that non-scientists like me can appreciate. www.curearthritis.org

We are honored by your support and the fact that you share with us a commitment to research as the means to finding new and better treatments for those suffering with arthritis.

Kevin P. Donohue, CFP®
President
TRANSPARENCY & ACCOUNTABILITY

Rated 4-stars by Charity Navigator

Transparency and accountability are extremely important to the Arthritis National Research Foundation. And, we are not the only ones who think so!

We have been named the “#1 Charity to Watch” in 2013 for charities with annual budgets under $2 million by Charity Navigator, the leading independent online charity evaluator.

In addition, Charity Navigator has awarded ANRF its highest rating of four stars five years in a row! Charity Navigator considers this an “exceptional” rating and defines charities with four stars as “exceeding industry standards and outperforming most charities in its Cause.” Please visit the Transparency and Accountability section on CureArthritis.org to learn more or to visit our Charity Navigator profile.

We want you to know that, when you give ANRF a gift, over 90% of it goes directly to arthritis research programs, not to overhead expenses.

“ANRF is the #1 Charity to watch for 2013!”

Our mission is to fund scientists to cure arthritis by discovering the causes of arthritis and its related diseases including osteoarthritis, rheumatoid arthritis, lupus, juvenile arthritis and other autoimmune diseases.

To accomplish this mission, your donations must go to arthritis research. You may hold ANRF accountable to utilize your donations wisely and to be transparent in the process. We are committed to using the donations you have entrusted to us efficiently and effectively in the effort to find a cure.

Research is the key to finding a cure for these diseases. Your donations make it possible and you have our promise – and Charity Navigator’s assessment – that we will spend your gift wisely.
# Financial Report 2012

**Audited Statement of Public Support, Fiscal Year Ending March 31, 2012**

## Revenues and Expenses

<table>
<thead>
<tr>
<th>Public Support and Revenue</th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and bequests</td>
<td>1,516,453</td>
<td>2,173,600</td>
</tr>
<tr>
<td>Investment Income</td>
<td>287,385</td>
<td>713,081</td>
</tr>
<tr>
<td>Unrealized Gain (loss) on Investments</td>
<td>(150,130)</td>
<td>536,457</td>
</tr>
</tbody>
</table>

**Total Support and Revenue**

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EXPENSES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program Services</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research</td>
<td>1,034,303</td>
<td>1,061,619</td>
</tr>
<tr>
<td>Education</td>
<td>197,758</td>
<td>140,280</td>
</tr>
<tr>
<td>Total Program Services</td>
<td>$1,232,061</td>
<td>$1,201,899</td>
</tr>
<tr>
<td><strong>SUPPORTING SERVICES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management and General</td>
<td>73,679</td>
<td>88,354</td>
</tr>
<tr>
<td>Fund Development</td>
<td>28,565</td>
<td>35,889</td>
</tr>
<tr>
<td>Total Supporting Services</td>
<td>$102,244</td>
<td>$124,243</td>
</tr>
</tbody>
</table>

**Total Expenses**

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in Unrestricted Net Assets</td>
<td>469,533</td>
<td>1,560,539</td>
</tr>
<tr>
<td>Net Assets at Beginning of Year</td>
<td>7,209,603</td>
<td>5,659,350</td>
</tr>
<tr>
<td>Net Assets at End of Year</td>
<td>7,679,136</td>
<td>7,209,603</td>
</tr>
</tbody>
</table>

## Statement of Financial Position 2012

### Assets

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalents</td>
<td>600,423</td>
<td>440,258</td>
</tr>
<tr>
<td>Accrued Interest</td>
<td>9,681</td>
<td>8,014</td>
</tr>
<tr>
<td>Investments</td>
<td>7,027,156</td>
<td>6,720,648</td>
</tr>
<tr>
<td>Note Receivable</td>
<td>56,415</td>
<td>56,415</td>
</tr>
<tr>
<td>Equipment</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>$7,693,675</td>
<td>$7,225,335</td>
</tr>
</tbody>
</table>

### Liabilities and Net Assets

#### Liabilities

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts Payable</td>
<td>4,253</td>
<td>5,446</td>
</tr>
</tbody>
</table>

#### Net Assets

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>7,679,136</td>
<td>7,209,603</td>
</tr>
</tbody>
</table>

**Total Liabilities and Net Assets**

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2011</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td>$7,693,675</td>
<td>$7,225,335</td>
</tr>
</tbody>
</table>
Massimo Bottini, PhD, of Sanford Burnham Medical Research Institute in La Jolla, California, was recently awarded a second consecutive year of funding by the Arthritis National Research Foundation for his research work in nanoparticles as related to autoimmune arthritis. In 2006, Massimo’s brother, Nunzio Bottini, MD, PhD was awarded a grant from the Arthritis National Research Foundation for his investigation into the PTPN22 gene that causes rheumatoid arthritis. Both of these young scientists, though working on different aspects of arthritis research, not only share a lineage, but also a passion for finding a cure for arthritis.

Massimo’s work is based in nanotechnology which is the manipulation of matter on a molecular scale. He creates nanoscopic particles (nanoparticles) to penetrate and carry information to cell subsets, called T cells, which reside in arthritic joints and trigger immune responses. While still a student, Massimo learned how powerful nanoparticles can be because they can deliver medicine directly into infected cells. If his research continues as planned, he hopes to have an answer in the next five years regarding whether boosting the activity of T cells in arthritic joints is beneficial to improving symptoms in patients.

Nunzio, now an associate professor at the La Jolla Institute for Allergy and Immunology, received his ANRF grant in 2006 when he was a researcher at the University of Southern California. At USC, he studied a gene, PTPN22, which increases the risk of rheumatoid arthritis. He still studies PTPN22, but his arthritis research has expanded to finding therapies that are less immunosuppressive than current remedies. PTPN22 is now known as the second-strongest arthritis causing gene among Caucasians, a fact attributed in part to Nunzio’s research.

“You don’t need to be sick, yourself, to understand the need to help sick people,” said Nunzio, about his work. “I can fight for them.”

Both brothers completed their education in Italy, moving to the U.S. to continue their research studies in 2000 and 2004, respectively.

They agree that seeing patients and peers who have suffered with arthritis is the main motivation for their work. Nunzio told ANRF that his research in the lab and clinic have given him a sense of usefulness and pride that he is doing good work. Massimo explained his commitment to arthritis: “I met a scientist in my lab that was diagnosed with arthritis but, because of her love for science, she continued to use tiny medical tools despite the pain and suffering they caused. She inspired me to apply my work in nanotechnology to find a cure for arthritis.”

"Both clinically and scientifically, arthritis is a complicated field and requires knowledge spanning several medical and scientific fields to make a correct diagnosis, or discover something relevant," Nunzio said. "Massimo is a bioengineer while I am a medical scientist, so scientifically we complement each other well."

Though the brothers focus on different aspects of arthritis research, they share common motivations and a common goal. From this perfect combination, collaboration began five years ago and has already resulted in several research papers published in journals and books. According to Massimo, both he and his brother are stubborn, but in a good way, which has kept them devoted to searching for a cure.

As with most siblings, there is a lighthearted, yet competitive sibling rivalry as to who can come up with the best ideas. At the end of the day, they always come together and, along with the Arthritis National Research Foundation, continue to be each others' biggest supporter.

“The ANRF grant encouraged me that my science was relevant and to keep going,” Nunzio said.

"ANRF adopted us and I wonder if any other organization has funded collaborating brothers," agreed Massimo. "I will never stop thanking them for enabling me to work on my projects."

Shortly after qualifying for a second year of funding from ANRF, Nunzio was awarded long-term funding for his work from the National Institutes of Health, thereby disqualifying him from receiving a second grant from ANRF. Massimo is a current ANRF grant recipient, continuing his groundbreaking work in nanotechnology. Read more at CureArthritis.org
Collaborative Research in Aging and Arthritis

The Arthritis National Research Foundation (ANRF) and the American Federation for Aging Research (AFAR) in New York, NY are collaborating to co-fund an Arthritis and Aging Research Grant. The Arthritis and Aging Research Grant provides $100,000 for one year to a young investigator at the assistant professor level studying the role of aging in the development of arthritis.

"This collaboration with the AFAR enables us to pool our resources and relationships within the scientific community to expand our outreach and opportunity for new knowledge in the field," said ANRF executive director Helene Bellisle.

Both organizations fund young investigators with new ideas "outside the box" of conventional and established thinking.

Both acknowledge that aging is a major risk factor for some forms of arthritis. Many forms of arthritis are strongly linked to aging but the mechanisms for this link are incompletely understood. With this grant for 2013-2014, AFAR and ANRF are supporting new research in this underexplored area.

This collaborative grant furthers the missions of both organizations. "We hope this partnership continues beyond this first, one-year grant," said Bellisle, "and that the new information uncovered will benefit those in our aging population who suffer the pain of arthritis."
Eleven scientists researching arthritis were awarded grants totaling $810,000 by the Arthritis National Research Foundation for fiscal 2011-12. Their work in osteoarthritis, rheumatoid arthritis, lupus, juvenile arthritis, gout and other autoimmune forms of arthritis holds the promise for new therapies.

The researchers funded this year represent the top 16% of all applicants. They are young, post-doctoral investigators with cutting-edge research ideas. ANRF’s highly competitive review process conducted by its world-renowned Scientific Advisory Board ensures that only the top applicants and projects are funded.

ANRF’s research grants give newer investigators a start on their independent research careers: this funding helps them perform cutting-edge experiments in top laboratory settings and gives them the tools they need to make discoveries that may lead to new treatments.

Einstein and Newton made their pivotal discoveries when they were young; the young scientists funded by ANRF may hold the key to a cure for arthritis. Read more about this year’s grant recipients at www.curearthritis.org.

<table>
<thead>
<tr>
<th>Area of Study</th>
<th>ANRF Scientist</th>
<th>Research Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatoid Arthritis</td>
<td>Massimo Bottini, Ph.D.</td>
<td>Sanford-Burnham Medical Research Institute</td>
</tr>
<tr>
<td></td>
<td>Gonghua Huang, Ph.D.</td>
<td>La Jolla, CA</td>
</tr>
<tr>
<td></td>
<td>Damini Jawaeher, Ph.D.</td>
<td>St. Jude Children’s Research Hospital</td>
</tr>
<tr>
<td></td>
<td>Hye-Jung Kim, Ph.D.</td>
<td>Memphis, TN</td>
</tr>
<tr>
<td></td>
<td>Lisa Peterson, Ph.D.</td>
<td>Children’s Hospital Oakland Research Institute</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oakland, CA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Juvenile Arthritis</td>
<td>Altan Ercan, Ph.D.</td>
<td>National Jewish Health</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Denver, CO</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>Andreia Ionescu, Ph.D.</td>
<td>Brigham &amp; Women’s Hospital</td>
</tr>
<tr>
<td></td>
<td>Yingcui Li, Ph.D.</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>Lupus</td>
<td>Stephen Gauld, Ph.D.</td>
<td>Harvard Medical School</td>
</tr>
<tr>
<td></td>
<td>Julie Zikherman, M.D.</td>
<td>Boston, MA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of Connecticut Health Center</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Farmington, CT</td>
</tr>
<tr>
<td>Gout</td>
<td>Laurent Reber, Ph.D.</td>
<td>Medical College of Wisconsin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Milwaukee, WI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of California</td>
</tr>
<tr>
<td></td>
<td></td>
<td>San Francisco, CA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stanford University</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stanford, CA</td>
</tr>
</tbody>
</table>
Scientist Targets Antibody Sugars in Juvenile Arthritis
Dr. Ercan is studying the changes in glycans (sugars) attached to IgG type antibodies. Immunoglobulin G (IgG) is an important contributor to inflammation within the joint. Its interaction with other molecules in the inflammatory process is strongly influenced by the structure of complex sugars attached to IgG. In adult rheumatoid arthritis (RA), it is well established that one class of the sugar structure (G0) is present in greater abundance in RA patients, suggesting that antibody sugars may be an important contributor to RA.

However, little is known about the same process in children. In the first year of his ANRF grant, Dr. Ercan investigated G0 sugars among healthy children and patients with juvenile idiopathic arthritis (JIA). According to his results, published recently in *Arthritis & Rheumatism*, an unusually elevated proportion of G0 is found in patients with multiple different forms of JIA.

Intriguingly, healthy children at the peak age of JIA onset (2-3 years) also showed a higher G0 proportion, suggesting one way in which the immature immune system may predispose children to arthritis.

Because he has been studying glycosylation since 2003 and, more specifically, IgG glycosylation since 2007, Dr. Ercan is considered an expert in his field. Last year he published two papers in scientific journals on these studies, including the one cited above.

"Patients are the strongest motivation for me as a human, as well as a scientist who works on the disease. This makes me look harder into every piece of data to understand it," says Dr. Ercan.

Dr. Ercan’s mother was recently diagnosed with osteoarthritis and, though his interest in finding a cure for the disease pre-dates her diagnosis, he is all the more fervent about finding a new treatment and/or cure. The prevalence of arthritis, the curious gender issue involved and the continuing mystery surrounding the cause of juvenile and adult arthritis all combine to fortify Dr. Ercan’s commitment to his studies.

"There is clearly a need for research in this area and I am happy to be doing it," he remarked.

Even if his research does not lead to a cure for those with juvenile and adult arthritis, Dr. Ercan believes that finding a cure is eminently as long as there is unyielding dedication and collaboration between organizations like ANRF and the scientists in the lab. “The more we learn about the mechanism of inflammation, the more drugs will be developed to treat arthritis patients. IgG glycosylation is one of the targets in managing inflammation in both juvenile and adult arthritis,” he added.

Dr. Ercan is taking great steps on the research front with the conviction and optimism that he will succeed. “Research is the answer for a cure.”

The Kelly Award for Juvenile Arthritis Research was established in 2010 to honor ANRF board member, Kelly Rouba, who was diagnosed with juvenile rheumatoid arthritis at age 2. The “can-do” spirit of this young woman who is a published author and advocate for people with disabilities inspired the Arthritis National Research Foundation to create a grant to specifically study juvenile arthritis. To learn more and support The Kelly Award, please visit CureArthritis.org.
"I am thrilled to have made an impact on arthritis research with my fundraiser and hope to do it again!"

Shelly Hallman, Long Beach Marathon

"Racing for a Cure was a cause that allowed me to give more purpose to my running. Running is a true celebration of the physical life we are given"

Kevin Tison, Long Beach Marathon

"My love of distance running brings awareness to arthritis. Wearing my Racing For A Cure jersey gives me the extra push I need to keep going for my team."

Leon Long, Las Vegas Ragnar Relay
THE FACTS

- 300,000 children have been diagnosed with juvenile arthritis
- 50 million Americans are afflicted with arthritis
- 67 million adults will be diagnosed with arthritis by 2030
- It’s time for a cure!

THE PROGRAM

- Pick a race (run, swim, bike, walk or triathlon)
- Visit CureArthritis.org/Racing-For-A-Cure to sign-up
- Tell us your race and your jersey/t-shirt size
- Setup a fundraising page (fundraising not required)
- RAISE TONS OF AWARENESS!

Full Details at CureArthritis.org/Racing-For-A-Cure
Christine Schwab, ANRF’s newest Advisory Board member, is living her dream. The dream she is living is to raise awareness and remove the stigma of the public’s perception when they hear the term “arthritis.”

Christine lives what some would call a charmed life. She is a TV personality and beauty expert, making countless appearances on shows like Live with Regis and Kelly and Oprah. She is highly regarded for her opinions on style in TV, books and various magazines like Redbook, O, the Oprah Magazine and recently, Arthritis Today. But Christine kept a secret. She had rheumatoid arthritis but no one “in the media business” knew for 20 years. She was first in line for the new biologic treatments for RA, participating in the clinical trial for Enbrel. Although she was given the placebo during the trial and suffered joint damage as a result, once the drug got FDA approval, Christine was among the first patients to receive the drug.

“These biologic drugs have given me my life back,” says Christine, who has been in remission since 1998.

The molecule blocked by the biologic drugs termed “anti-TNF” is Tumor Necrosis Factor or lymphotoxin, discovered in 1969 by ANRF grant recipient and longtime Board and Scientific Advisory Board member, Gale A. “Morrie” Granger, PhD.

“Meeting Dr. Granger and being able to personally thank him for his discovery meant the world to me,” Christine continued. “The more I learned about ANRF, the more I wanted to become involved.”

To lend her support and celebrity to arthritis research, Christine joined the ANRF’s Advisory Board earlier this year. But every day, she is living her dream to change the public’s opinion of what it means to have arthritis. She is a three-time published author whose latest book is about her arthritis journey. Take Me Home from the Oscars gives arthritis patients insight and hope.

“It’s not your grandma’s arthritis anymore,” says Christine. “It afflicts 300,000 children, young adults and people of all ages. And, arthritis doesn’t have to keep you from your dreams. With hope, perseverance and research I have my life back and no one lives this message more than the incredible children and young people I’ve met through Christine’s Kids.”

Christine’s Kids is Christine’s Facebook page dedicated to kids and teens with juvenile arthritis and their families. It has become a focal point of her awareness efforts and she has thousands of followers who benefit from her personal contact, the news she posts and interacting with each other.

Christine now uses her TV celebrity to share her message of hope and awareness. She appears on shows like The Doctors, The Talk, Fox Network News, at events and online in presentations and through social networking to make this happen. ANRF is honored to have her help as it funds the research so critical to finding a cure.

To learn more about Christine visit ChristineSchwab.com or CureArthritis.org/anrf-welcomes-christine-schwab/
The Arthritis National Research Foundation (ANRF) is proud to announce the official launch of the Cure Arthritis Action Pak – an arthritis awareness kit full of “Cure Arthritis” branded merchandise that empowers supporters and those suffering with arthritis to spread the message that it is time to cure arthritis! The pak launched on May 1st in order to coincide with the beginning of Arthritis Awareness Month.

For a donation of $25, the Cure Arthritis Action Pak will be delivered to supporters and includes: a t-shirt, two buttons, two posters, five bracelets, four square stickers, a bumper sticker, and information on how to share your arthritis story to help find a cure. Each $25 donation funds one hour of arthritis research for Arthritis National Research Foundation scientists working in laboratories to make new discoveries for osteoarthritis, rheumatoid arthritis, lupus, juvenile arthritis, gout and related autoimmune diseases.

“We are very excited about the Action Pak,” said Helene Bellisle, Executive Director for the Arthritis National Research Foundation, “together we can create a voice to tell the world it’s time for a cure!”

Cure Arthritis Action Pak purchasers are considered Cure Arthritis Ambassadors, part of a team of individuals nationwide who are ready to tell the world it’s time for a cure. Cure Arthritis Team Ambassadors will use the contents in the Pak to help spread arthritis awareness and the message that research is the key to finding a cure.

Become an ambassador for change by purchasing your Cure Arthritis Action Pak today! At CureArthritis.org/action-pak
91 CENTS OF EVERY DOLLAR IS PLACED INTO RESEARCH

ARTHritIS NaTIONAL RESEARCH FOUNDATION
200 Ocean Gate, Suite 830 • Long Beach, CA 90802-4335 • 800-588-CURE

OFFICERS AND DIRECTORS

Kevin Donohue, President
Morgan Stanley Smith Barney

Shaun Skeris, Vice-President
River Eagle Advisors

Kelly Roush, 2nd Vice-President
NJ Division of Developmental Disabilities

Mark Schulten, Treasurer
Wells Fargo Advisors - The Schulten Group

Helene Bellisle, Executive Director
Arthritis National Research Foundation

Vic Braden
Vic Braden Tennis Colleges

Kathryn Ferris
Morgan Stanley Smith Barney

Gale Granger, Ph.D.
University of California, Irvine

Marli Kupin
Kupin Partners LLC

Krisy McPherson
LPGA Golf Professional

Britt Meyer
Meyer Properties

Lynn Moyer
Attorney at Law

James Rose, Pharm.D.
CareMore Health Plan

Debra Sampson
Community Advocate

The Hon. Sally Anne Sheridan
Hart Real Estate Group

Bennet Tchakolovsky
Worldwide Officers

Kathleen Tepley
Los Angeles Consulting Group

Carl F. Ware, Ph.D.
Sanford-Burnham Medical Research Institute

SCIENTIFIC ADVISORY BOARD

Carl F. Ware, Ph.D., Chairman
Sanford-Burnham Medical Research Institute

Joel Buxbaum, M.D.
The Scripps Research Institute

Mary K. Crow, M.D.
Hospital for Special Surgery

Bevra Hahn, M.D.
UCLA School of Medicine

Hal Hoffman, M.D.
University of California, San Diego

Martin K. Lotz, M.D.
The Scripps Research Institute

Hugh O. McDevitt, M.D.
Stanford University Medical Center

Grete Sondersrup-McDevitt, M.D.
Stanford University Medical Center

Robert Tordella, M.D.
University of California, San Diego

Emeritus

Gale Granger, Ph.D.
University of California, Irvine

Eng Tan, M.D.
The Scripps Research Institute

A portion of this annual report generously underwritten by

psp
print solutions provider

“Our mission is a simple one... use our expertise to create marketing tools that work better to attract... to educate... to inspire.”

OPTION DESIGN PRINT APPLIANCE
New ideas... better solutions.

info@printsolutionpr.com
www.printsolutionpr.com

Special thanks to our CFC donors!
CFC # 11031
Please remember us again this fall!